INVO Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (Nasdaq: INVO) on July 7, 2023. The filing discloses the entry into a material definitive agreement with Armistice Capital Markets Ltd. regarding a prior securities purchase agreement.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or margins. The primary financial obligation disclosed is a one-time fee of $1,000,000 (the "Armistice Amendment Fee") payable to Armistice within two days of the closing of a concurrent offering.
Material Changes and Agreements
- Amendment to Securities Purchase Agreement: The Company amended its March 23, 2023 agreement with Armistice to delete the "Subsequent Equity Financing Provision," which previously restricted the issuance of new equity for 45 days after the effective date of a Resale Registration Statement.
- Consideration: In exchange for removing the financing restriction, the Company agreed to pay the $1,000,000 fee.
- Warrant Exercise Price Reduction: The Company agreed to seek shareholder approval to reduce the exercise price of existing warrants issued to Armistice to the per-unit public offering price of the current offering, in compliance with Nasdaq Rule 5635(d).
- Shareholder Approval Mechanism: If approval is not obtained at the 2023 Annual Meeting, the Company must call a meeting every six months until approval is granted or the warrants expire. Until approved, the warrant exercise price remains unchanged.
- Payoff Commitment: A Payoff Commitment Agreement and Confession of Judgment were executed, allowing Armistice to obtain a judgment against the Company if the $1,000,000 fee is not paid when due.
Guidance, Risks, and Contingencies
The filing does not contain forward-looking guidance, revenue outlook, or management commentary on operational performance. The primary contingency identified is the requirement to obtain shareholder approval for the warrant price reduction; failure to secure this approval will result in recurring shareholder meetings every six months. Additionally, the Confession of Judgment creates a legal risk of immediate enforcement by Armistice in the event of non-payment of the amendment fee.
Key Facts for Investor Verification
- Verify the closing status of the offering referenced in the amendment to confirm the $1,000,000 fee payment timeline.
- Review the proxy statement for the 2023 Annual Meeting to confirm the proposal details regarding the warrant exercise price reduction.
- Assess the impact of the deleted "Subsequent Equity Financing Provision" on the Company's ability to raise capital in the near term.
- Monitor the status of the "Existing Warrants" and the potential dilution resulting from the proposed exercise price reduction.